Krystal Biotech Inc (KRYS)

Cash ratio

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash and cash equivalents	US$ in thousands	358,328	161,900	341,246	268,269	187,514
Short-term investments	US$ in thousands	173,872	217,300	96,854	3,031	6,186
Total current liabilities	US$ in thousands	33,094	28,847	25,736	15,452	3,327
Cash ratio		16.08	13.15	17.02	17.56	58.22

December 31, 2023 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($358,328K + $173,872K) ÷ $33,094K
= 16.08

The cash ratio of Krystal Biotech Inc has exhibited fluctuations over the past five years. The ratio stood at 16.08 on Dec 31, 2023, indicating that the company had $16.08 in cash and cash equivalents for every dollar of current liabilities. This represents an improvement compared to the previous year when the cash ratio was 13.15.

While the company's cash ratio has varied, it has generally remained at levels that suggest Krystal Biotech Inc has maintained a strong ability to cover its short-term obligations with its available cash resources. The significant decrease in the cash ratio from 58.22 in 2019 to 16.08 in 2023, however, may warrant further investigation into the company's liquidity position and cash management practices.

Overall, a cash ratio above 1 indicates that Krystal Biotech Inc has sufficient cash to cover its short-term liabilities, although investors and analysts should consider other liquidity ratios and financial metrics in conjunction with the cash ratio to gain a comprehensive understanding of the company's financial health.